KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

J Clin Oncol · 2026-Jan-20 · PMID 41370738

Panel C提取完成待 EXE 对齐验证

OS

FIG 3. (A) Response rates, (B) MRD negativity rates, and (C) OS in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b Includes two additional patients who had not yet been randomly assigned at the time of the primary analysis data cutoff date. CR, complete response; HR, hazard ratio; MRD, minimal residual disease; NE, not evaluable; ORR, overall response rate; OS, overall survival; PD, progressive disease; PomDex, pomalidomide and dexamethasone; PR, partial response; sCR, stringent complete response; VenDex, venetoclax and dexamethasone; VGPR, very good PR.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:02:33+00:00